

1     **Development and validation of treatment-decision algorithms for children evaluated for**  
2     **pulmonary tuberculosis: an individual participant data meta-analysis**

3     Kenneth S. Gunasekera, Olivier Marcy, Johanna Muñoz, Elisa Lopez-Varela, Moorine P.  
4     Sekadde, Molly F. Franke, Maryline Bonnet, Shakil Ahmed, Farhana Amanullah, Aliya Anwar,  
5     Orvalho Augusto, Rafaela Baroni Aurilio, Sayera Banu, Iraj Batool, Annemieke Brands, Kevin P.  
6     Cain, Lucía Carratalá-Castro, Maxine Caws, Eleanor S. Click, Lisa M. Cranmer, Alberto L.  
7     García-Basteiro, Anneke C. Hesseling, Julie Huynh, Senjuti Kabir, Leonid Lecca, Anna  
8     Mandalakas, Farai Mavhunga, Aye Aye Myint, Kyaw Myo, Dorah Nampijja, Mark P. Nicol,  
9     Patrick Orikiriza, Megan Palmer, Clemax Couto Sant'Anna, Sara Ahmed Siddiqui, Jonathan P.  
10    Smith, Rinn Song, Nguyen Thuy Thuong Thuong, Vibol Ung, Marieke M. van der Zalm, Sabine  
11    Verkuijl, Kerri Viney, Elisabetta G. Walters, Joshua L. Warren, Heather J. Zar, Ben J. Marais,  
12    Stephen M. Graham, Thomas P. A. Debray, Ted Cohen, James A. Seddon

13  
14    **Author Affiliations**

15    Listed at end of document

16    **Keywords**

17    Diagnostic algorithm, diagnostic system, tuberculosis, paediatric, clinical evidence, Diagnosis/\*  
18    clinical decision-making

19    **Word count**

20    Abstract: 300/300

21    Main article 3500/3500

22    References: 30

23    Figures: 3

24    Tables: 3

25    **Corresponding author**

26    Kenneth Gunasekera

27    350 George Street, 3F

28    New Haven, CT 06510

29    USA

30    e-mail: [kenneth.gunasekera@yale.edu](mailto:kenneth.gunasekera@yale.edu)

31 **ABSTRACT**

32 **Background:** Many children with pulmonary tuberculosis remain undiagnosed and  
33 untreated with related high morbidity and mortality. Diagnostic challenges in children include low  
34 bacterial burden, challenges around specimen collection, and limited access to diagnostic  
35 expertise. Algorithms that guide decisions to initiate tuberculosis treatment in resource-limited  
36 settings could help to close the persistent childhood tuberculosis treatment gap. Recent  
37 advances in childhood tuberculosis algorithm development have incorporated prediction  
38 modelling, but studies conducted to date have been small and localised, with limited  
39 generalizability.

40 **Methods:** We collated individual participant data including clinical, bacteriological, and  
41 radiologic information from prospective diagnostic studies in high-tuberculosis incidence settings  
42 enrolling children <10 years with presumptive pulmonary tuberculosis. Using this dataset, we  
43 first retrospectively evaluated the performance of several existing treatment-decision algorithms  
44 and then developed multivariable prediction models, investigating model generalisability using  
45 internal-external cross-validation. A team of experts provided input to adapt the models into a  
46 pragmatic treatment-decision algorithm with a pre-determined sensitivity threshold of 85% for  
47 use in resource-limited, primary healthcare settings.

48 **Findings:** Of 4,718 children from 13 studies from 12 countries, 1,811 (38.4%) were  
49 classified as having pulmonary tuberculosis; 541 (29.9%) bacteriologically confirmed and 1,270  
50 (70.1%) unconfirmed. Existing treatment-decision algorithms had highly variable diagnostic  
51 performance. Our prediction model had a combined sensitivity of 86% [95% confidence interval  
52 (CI): 0.68-0.94] and specificity of 37% [95% CI: 0.15-0.66] against a composite reference  
53 standard.

54 **Interpretation:** We adopted an evidence-based approach to develop pragmatic  
55 algorithms to guide tuberculosis treatment decisions in children, irrespective of the resources  
56 locally available. This approach will empower health workers in resource-limited, primary

57 healthcare settings to initiate tuberculosis treatment in children in order to improve access to  
58 care and reduce tuberculosis-related mortality. These algorithms have been included in the  
59 operational handbook accompanying the latest WHO guidelines on the management of  
60 tuberculosis in children and adolescents.

61 **Funding:** World Health Organization, US National Institutes of Health

## 62 RESEARCH IN CONTEXT

63 **Evidence before the study:** Treatment-decision algorithms relate information gained in  
64 the evaluation of children into an assessment of tuberculosis disease risk and empower  
65 healthcare workers to make appropriate treatment decisions. Studies in primary healthcare  
66 centres have demonstrated that use of treatment-decision algorithms can improve childhood  
67 pulmonary tuberculosis case-detection and treatment initiation in settings with high-tuberculosis  
68 incidence. To identify primary research studies on treatment-decision algorithm performance  
69 evaluation and/or development for childhood pulmonary tuberculosis, we carried out a PubMed  
70 search using the terms ('child\*' OR 'paediatr\*' OR 'pediatr\*') AND ('tuberculosis' OR 'TB') AND  
71 ('treatment-decision' OR 'algorithm' OR 'diagnos\*') to identify primary research published in any  
72 language prior to 29 June 2022.

73 We additionally consulted multiple experts in childhood pulmonary tuberculosis  
74 diagnosis and management, and we referred to existing, published reviews of treatment-  
75 decision algorithms. With respect to treatment-decision algorithm performance, several studies  
76 have retrospectively estimated the performance of treatment-decision algorithms in a single  
77 geographic setting; a subset of these studies have also compared the performance of multiple  
78 algorithms using data from a single geographic setting. With respect to treatment-decision  
79 algorithm development, many existing algorithms have been developed without explicit analysis  
80 of data from children with presumptive pulmonary tuberculosis, often developed from expert  
81 consensus. Gunasekera et al. used model-based approaches to analyse diagnostic evaluations  
82 data (e.g., clinical history, physical examination, chest radiograph, and results from rapid  
83 molecular and culture testing for *Mycobacterium tuberculosis*) collected from children with  
84 presumptive pulmonary tuberculosis in a single geographic setting to inform the development of  
85 a diagnostic algorithm while Marcy et al. and Fourie et al analysed data from multiple  
86 geographic settings. However, these studies were relatively small with limited assessment of  
87 generalisability.

88           **Added value of this study:** We collated individual participant data from 13 prospective  
89 diagnostic studies from 12 countries including 4,718 children with presumptive pulmonary  
90 tuberculosis from geographically diverse settings with a high incidence of tuberculosis in order  
91 to 1) evaluate the performance of existing treatment-decision algorithms and 2) develop  
92 multivariable logistic regression models to quantify the contribution of individual features to  
93 discriminate tuberculosis from non-tuberculosis. A panel of child tuberculosis experts provided  
94 input into performance targets and advised on how to incorporate scores derived from these  
95 models into pragmatic treatment-decision algorithms to assist in the evaluation of children  
96 presenting with presumptive pulmonary tuberculosis in primary healthcare centres.

97           **Implications of all the available evidence:** Our findings suggest that evidence-based,  
98 pragmatic treatment-decision algorithms can be developed to make sensitive and clinically  
99 appropriate decisions to treat a child with pulmonary tuberculosis. Although the specificity does  
100 not reach optimal targets for childhood tuberculosis diagnosis, pragmatic treatment-decision  
101 algorithms provide clinically relevant guidance that can empower health workers to start children  
102 on tuberculosis treatment at the primary healthcare setting and will likely contribute to reducing  
103 the case-detection gap in childhood tuberculosis. External, prospective evaluation of these  
104 novel algorithms in diverse settings is required, including assessment of their accuracy,  
105 feasibility, acceptability, impact, and cost-effectiveness. This work led to a new interim WHO  
106 recommendation to support the use of treatment-decision algorithms in the evaluation of  
107 children with presumptive tuberculosis in the 2022 updated consolidated guidelines on the  
108 management of tuberculosis in children. Two algorithms developed from this work have been  
109 included in the WHO operational handbook accompanying these guidelines.

## 110 INTRODUCTION

111 Tuberculosis is a leading cause of mortality among children worldwide,<sup>1</sup> accounting for  
112 ~2.5% of the 6 million deaths in children <5 years each year.<sup>2</sup> Modelling suggests that more  
113 than 96% of tuberculosis deaths in children and adolescents (<15 years) occurred in those not  
114 receiving tuberculosis treatment.<sup>3</sup> The World Health Organization (WHO) estimates that fewer  
115 than 50% of the 1.1 million children <15 years who develop tuberculosis are diagnosed; the  
116 proportion is even lower among children <5 years, at about 27%.<sup>1</sup> Thus, efforts to improve  
117 diagnosis, and thereby improve access to tuberculosis treatment, are an important opportunity  
118 to reduce tuberculosis morbidity and deaths among children.

119 Diagnosing pulmonary tuberculosis among children is challenging as respiratory  
120 specimens tend to be paucibacillary, resulting in a low yield of bacteriologic confirmation.<sup>4</sup>  
121 Furthermore, collecting respiratory specimens from young children is invasive and requires  
122 resources that are generally concentrated in higher-level healthcare centres. Thus, careful  
123 symptom review, clinical examination, chest radiography, and history of *Mycobacterium*  
124 *tuberculosis (Mtb)* exposure can inform treatment decisions in clinical care. However, paediatric  
125 clinical expertise and resources to make a diagnosis are often limited at primary healthcare  
126 centres. This limits treatment access and leads to either delays in treatment initiation or no  
127 treatment initiation which are associated with worse outcomes, including mortality.<sup>5,6</sup> Facilitating  
128 appropriate diagnostic assessment with rapid treatment initiation at healthcare settings where  
129 children initially present could contribute to reductions in tuberculosis-related morbidity and  
130 mortality.

131 Treatment-decision algorithms aim to standardise clinical assessment and decision-  
132 making. Algorithms relate information gained in the evaluation of children into an assessment of  
133 tuberculosis disease risk and empower healthcare workers to make appropriate treatment  
134 decisions. Adopting an algorithmic approach to treatment decision-making has been shown to  
135 improve childhood tuberculosis case detection and treatment access at primary healthcare

136 settings.<sup>7,8</sup> However, these algorithms were developed using consensus expert opinion rather  
137 than analysis of data.

138         Recent approaches for algorithm generation have used data from cross-sectional  
139 childhood tuberculosis diagnostic studies to quantify the contribution of clinical characteristics to  
140 the risk of tuberculosis disease.<sup>9-11</sup> Evidence-based approaches are objective and offer the  
141 potential for validation; however, existing studies have been small and not generalisable. In this  
142 study, we assembled individual participant data (IPD) from children investigated for presumptive  
143 pulmonary tuberculosis. We then sought to first evaluate the performance of currently used  
144 diagnostic algorithms and then develop evidence-based treatment-decision algorithms. This  
145 work was conducted to inform the 2022 WHO guidelines for the management of tuberculosis in  
146 children and adolescents and the accompanying WHO operational handbook.<sup>12,13</sup>

## 147 **METHODS**

### 148 *Establishment of individual participant data*

149         We identified potential sources of IPD through responses to a public WHO Global  
150 Tuberculosis Programme Public Call for Data on the Management of Children with Tuberculosis  
151 in July 2020 and through referral from paediatric tuberculosis experts. Studies were eligible for  
152 inclusion if they 1) prospectively recruited consecutive participants <10 years (the definition of a  
153 child in the 2022 WHO guideline) attending healthcare centres in high-tuberculosis incidence  
154 countries for clinical evaluation of pulmonary tuberculosis and 2) provided a final research  
155 classification of pulmonary tuberculosis for each child. Tuberculosis was classified using the  
156 revised US National Institutes of Health (NIH) clinical case definitions of intrathoracic  
157 tuberculosis in children.<sup>14</sup> Broadly, this defines a confirmed tuberculosis case as culture- or  
158 Xpert MTB/RIF-confirmed *Mtb* from respiratory specimen(s); an unconfirmed tuberculosis case  
159 as having symptoms, chest radiography findings, and/or immune tests of *Mtb* sensitivity  
160 suggestive of tuberculosis (including follow-up to verify or rule out tuberculosis); and an unlikely

161 tuberculosis case as meeting criteria for neither confirmed nor unconfirmed tuberculosis. If the  
162 study did not use the NIH classification, we used the study-specific definition of unconfirmed  
163 tuberculosis and unlikely tuberculosis. Quality assessment was performed using a modified  
164 version of the Newcastle-Ottawa Scale for cohort studies.<sup>15</sup>

165         After identification of eligible studies, we requested IPD including details from the clinical  
166 history, physical examination, chest radiograph, and results from rapid molecular and culture  
167 testing for *Mtb* performed on respiratory specimens collected at study entry (Supplementary  
168 Appendix A). All data assembly and analysis were carried out using R software version 4.1.1.  
169 To account for the uncertainty associated with incomplete data, we used multilevel multiple  
170 imputation by chained equations (MICE) implemented in the *MICE* package to generate 100  
171 imputed datasets (Supplementary Appendix B).<sup>16</sup>

#### 172 *Evaluation of existing treatment-decision algorithms*

173         We identified existing treatment-decision algorithms and scores (henceforth referred to  
174 as algorithms) to guide the evaluation of children with presumptive pulmonary tuberculosis  
175 through consultation with members of the WHO Guideline Development Group (GDG) on the  
176 management of tuberculosis in children and adolescents. We defined a composite reference  
177 standard using the NIH definitions of confirmed and unconfirmed pulmonary tuberculosis to  
178 evaluate the performance of these algorithms. We carried out a sensitivity analysis of  
179 performance using a reference standard of confirmed pulmonary tuberculosis only (excluding  
180 children with unconfirmed tuberculosis). We used the “reitsma” function from the R package  
181 *mada* to pool study-level sensitivity and specificity estimates using a bivariate random effects  
182 meta-analysis (Supplementary Appendix C).<sup>17,18</sup>

#### 183 *Prediction model development and validation*

184         We developed a multivariable logistic regression model to predict pulmonary  
185 tuberculosis using the composite reference standard in accordance with the Transparent



186 Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis standards  
187 using the internal-external cross-validation framework.<sup>19,20</sup> Predictors included clinical features  
188 commonly considered in the evaluation of presumptive childhood pulmonary tuberculosis in  
189 primary and secondary healthcare centres that were available in the data with <50%  
190 missingness. We also built a model without chest radiograph data to inform predictions in  
191 healthcare centres without access to radiology services.

192 To account for possible heterogeneity in the distribution of predictor and outcome  
193 variables, we fit the prediction model separately in each study and subsequently pooled their  
194 regression coefficients and respective standard errors. This approach was implemented in the  
195 “metapred” function of package *metamisc*.<sup>20,21</sup> To account for missing data, we generated a  
196 prediction model as described above from each of the 100 imputed datasets and then used  
197 Rubin’s rules to pool the regression coefficients and standard errors to generate a final, single  
198 prediction model and compute odds ratios with 95% confidence interval (95% CI).<sup>22</sup> We  
199 examined the c-statistic (also known as the area under the receiver operating characteristic  
200 curve) to assess the model’s ability to distinguish between children with tuberculosis and  
201 unlikely tuberculosis, and we examined the observed:expected (O:E) ratio to assess whether  
202 there were studies in which the model over- or under-predicted tuberculosis.

### 203 *Algorithm development*

204 To generate clinically and programmatically implementable algorithms, we scaled the  
205 coefficient estimates for the parameters of the final prediction models (developed from all  $n$   
206 studies) to estimate scores for each parameter such that a combined score of >10  
207 corresponded to classification of tuberculosis at fixed sensitivities of 90%, 85%, 80%, 75%, and  
208 70% (Supplementary Appendix D). To estimate the sensitivity and specificity of the score in  
209 classifying tuberculosis using the composite reference standard, study-level sensitivities and  
210 specificities were pooled using the bivariate model of Reitsma et al. (implemented in the *mada*  
211 package) accounting for uncertainty introduced by imputation of missing data.<sup>17,18</sup> As a

212 sensitivity analysis, we evaluated the performance of the score against a reference standard of  
213 confirmed pulmonary tuberculosis only.

214 We worked with staff from the WHO Global TB Programme to identify a group of experts  
215 in childhood tuberculosis (henceforth referred to as the expert group; Supplementary Appendix  
216 E) to advise on the development of two treatment-decision algorithms from these scores.  
217 Specifically, we sought advice on how to use this score within an algorithm intended to be used  
218 at primary healthcare centres and on selection of a performance target for the development of  
219 the score to be included within the algorithm.

## 220 *Ethics*

221 This study was approved by the Stellenbosch University Health Research Ethics  
222 Committee (Ref No. X21/02/003) and the Yale Institutional Review Board (Ref No.  
223 2000028046). All collaborating investigators confirmed institutional ethical approval for their  
224 original data collection.

## 225 **RESULTS**

### 226 *Data assembly*

227 Eighteen studies were identified as having potentially appropriate data, largely sourced  
228 from diagnostic evaluation studies. The study investigators for two studies were unable to  
229 provide data in the necessary timeline and an additional three studies did not meet the inclusion  
230 criteria. From the 13 included studies carried out in 12 countries, 4,718 IPD records from  
231 children <10 years with presumptive pulmonary tuberculosis were available, of which, 541  
232 (11.5%) were classified as having confirmed tuberculosis, 1,270 (26.9%) as having unconfirmed  
233 tuberculosis and 2,818 (59.7%) unlikely tuberculosis (**Tables 1 and 2**; Supplementary  
234 Appendices F and G). The data were predominantly collected at secondary or tertiary/referral  
235 healthcare centres. Although each study was required to include children with presumptive  
236 pulmonary tuberculosis, studies differed slightly with respect to inclusion criteria, variable

237 definitions, and reference classification of tuberculosis ([Supplementary Appendices H-K](#)). All  
238 contributing studies achieved quality assessment scores of 4/5 or 5/5. ([Supplementary](#)  
239 [Appendix L](#)).

#### 240 *Existing treatment-decision algorithm performance*

241 We evaluated the performance of eight existing treatment-decision algorithms. One of  
242 these algorithms was evaluated only on data from children living with HIV, and another  
243 evaluated only on data from children without HIV. Because some algorithms considered  
244 evidence that were not available in the IPD, we modified all algorithms slightly ([Supplementary](#)  
245 [Appendix M](#)). The sensitivities varied from 17% to 93% with specificities varying from 88% to  
246 16% when evaluated against the composite reference standard (**Figure 1**; [Supplementary](#)  
247 [Appendix N](#)). A sensitivity analysis evaluating performance to discriminate confirmed  
248 tuberculosis from unlikely tuberculosis demonstrated marginally higher sensitivities and  
249 comparable specificities to the performance in the entire dataset ([Supplementary Appendix O](#)).

#### 250 *Prediction model development and validation*

251 Odds ratios and 95% CI of the predictors included in the model are displayed in **Table 3**.  
252 The pooled c-statistic for the prediction model including chest x-ray features was 0.71 (95% CI:  
253 0.66-0.76), with a summary O:E ratio of 0.90 (95% CI: 0.28-2.98). Additional internal-external  
254 cross-validation c-statistic and O:E ratio estimates are included in [Supplementary Appendix P](#).  
255 Estimates for the model without chest x-ray features are included in [Supplementary Appendix](#)  
256 [Q](#).

#### 257 *Algorithm development*

258 The scores derived from the model prediction coefficients that correspond to  
259 classification of all tuberculosis with respective sensitivities of 90%, 85%, 80%, 75%, and 70%  
260 can be found in [Supplementary Appendix R](#). The study-level and summary performance of  
261 these scores in classifying tuberculosis can be found in [Supplementary Appendix S](#).

262 To balance the consequences of untreated tuberculosis versus the consequences of  
263 overtreatment, the expert group recommended a sensitivity threshold of 85% in classifying  
264 tuberculosis using the composite reference standard, resulting in the development of a score  
265 with a sensitivity of 0.86 (95% CI: 0.68-0.94) and a specificity of 0.37 (95% CI: 0.15-0.66)  
266 (**Figure 2**). An analysis of the performance in classifying confirmed tuberculosis vs. unlikely  
267 tuberculosis demonstrated a sensitivity of 0.88 (95% CI: 0.71-0.95) and specificity of 0.37 (95%  
268 CI: 0.15-0.67) (Supplementary Appendix T). Under a sensitivity threshold of 85%, the model that  
269 included only features from the baseline clinical evaluation (without chest x-ray findings) had a  
270 sensitivity of 0.84 (95% CI: 0.66-0.93) and specificity of 0.30 (95% CI: 0.13-0.56) in classifying  
271 tuberculosis (Supplementary Appendix U).

272 To adapt the scores into treatment-decision algorithms to be used at primary healthcare  
273 centres, the expert group recommended the following triage steps prior to classification using  
274 the score: 1) identifying children with clinical symptoms and signs requiring urgent referral to  
275 higher levels of healthcare, and 2) stratifying children by risk of mortality and progression of  
276 tuberculosis. Higher-risk children were defined by the expert group as those <2 years, severely  
277 malnourished, and/or living with HIV. These children would be evaluated using the score at the  
278 time of the initial evaluation. Children not meeting this definition would be treated for the most  
279 likely non-tuberculosis condition and complete re-evaluation in 1-2 weeks: those with  
280 persistent/worsening symptoms at follow-up would be evaluated using the score. The expert  
281 group additionally recommended to pursue, wherever available, bacteriological testing on  
282 respiratory and/or stool specimens with rapid molecular diagnostics for all children and urine  
283 lateral flow assays for HIV-positive children to align with existing WHO recommendations<sup>23</sup>.

284 The expert group recommendations resulted in the development of a treatment-decision  
285 algorithm (**Figure 3**), in which children <10 years with presumptive pulmonary tuberculosis are  
286 triaged by risk of tuberculosis-related morbidity and mortality prior to being evaluated for the  
287 presence of clinical and chest x-ray features to assign a score corresponding to tuberculosis

288 risk. A total score of >10 results in classification of tuberculosis with a sensitivity of 85%. Known  
289 exposure to tuberculosis alone has a score >10, so this was placed above the other elements.  
290 The same parameters were used to construct the treatment-decision algorithm from the model  
291 without chest x-ray features ([Supplementary Appendix V](#)).

## 292 **DISCUSSION**

293 We assembled a large IPD dataset from nearly five thousand children from  
294 geographically diverse, high-tuberculosis incidence settings to evaluate existing treatment-  
295 decision algorithms and develop new evidence-based treatment-decision algorithms to guide  
296 evaluation of children with presumptive pulmonary tuberculosis. This algorithm-building  
297 approach uses the best currently available data to provide practical guidance to healthcare  
298 workers in primary healthcare settings to identify which clinical features, with or without chest x-  
299 ray assessment, indicate whether initiation of tuberculosis treatment is warranted. The newly  
300 developed algorithms were incorporated into the WHO operational handbook to support  
301 implementation of the new consolidated guidelines.<sup>12,13</sup>

302 Modelling diagnostic evaluations IPD provides a quantitative description of the strength  
303 of evidence for childhood pulmonary tuberculosis treatment-initiation decisions. Of the clinical  
304 features, only reported exposure to tuberculosis was independently sufficient to meet the  
305 threshold for treatment initiation. This was true even in the model-based score without chest x-  
306 ray features, suggesting that none of the common clinical features could independently inform  
307 highly sensitive/specific treatment decisions. While results from tuberculin skin testing were  
308 used by studies to inform classification of tuberculosis and to improve imputation of missing  
309 data, we did not include these in the algorithms given operational limitations in using tuberculin  
310 skin testing at scale in high-burden settings. Of the chest X-ray features included in the  
311 algorithm, the presence of intrathoracic lymphadenopathy and a miliary pattern, respectively,  
312 were independently sufficient to start treatment. It is worth noting that inclusion of chest x-ray

313 features only increased the specificity of the score slightly as compared to the score developed  
314 from the model with clinical features only. Chest x-ray has additional utility in guiding childhood  
315 pulmonary tuberculosis treatment duration for severe vs. non-severe disease,<sup>24</sup> in monitoring TB  
316 treatment response (including associated complications and sequelae) and in the diagnosis of  
317 other non-tuberculosis intrathoracic pathology.

318         The decision to prioritise sensitivity in our algorithm development is critical to initiate  
319 more children with tuberculosis on appropriate therapy; however, many children may be falsely  
320 treated for tuberculosis given the resulting specificity. No test or algorithm meets the WHO-  
321 target sensitivity and specificity for a confirmatory diagnostic test for childhood pulmonary  
322 tuberculosis.<sup>25</sup> Thus, the expert group advised to develop an algorithm with a minimum  
323 sensitivity target of 85% as an acceptable balance between sensitivity and the resulting  
324 specificity. Tuberculosis treatment for drug-susceptible disease is relatively safe in children;<sup>26</sup>  
325 especially considering the potentially severe consequences of a missed tuberculosis diagnosis.  
326 However, falsely treating for tuberculosis carries risk of delayed diagnosis of other disease, drug  
327 adverse events, and unnecessary burden on families and healthcare services. It should be  
328 noted that while these performance estimates relate to the score component of the algorithm,  
329 the overall sensitivity and specificity of the whole algorithm, including the triage steps, remains  
330 unknown and should be evaluated prospectively. As low-risk children are made to wait prior to  
331 being evaluated with the scored part of the algorithm, symptoms in some with diagnoses other  
332 than tuberculosis will resolve, likely improving specificity.

333         We note that the model-based scoring component of the algorithm demonstrates  
334 considerable study-level heterogeneity in sensitivity and specificity. Although this IPD is the  
335 largest of its size compiled to date, there were not enough studies to quantitatively describe the  
336 features that drive the observed heterogeneity. Given that we used data made available to  
337 WHO following a public call rather than conducting a systematic review, it is possible that some  
338 diagnostic studies may have been excluded. The inclusion of more data from existing, ongoing,

339 and future studies, may allow meta-regression to describe study-level sources of heterogeneity.  
340 Heterogeneity may have been driven in part by varied tuberculosis prevalence in the cohorts  
341 included as well as heterogeneities in disease presentation. Given that the pre-existing  
342 treatment-decision algorithms demonstrated similar heterogeneities in performance compared  
343 to the evidence-based algorithm developed, we suggest that our approach is robust as it offers  
344 the flexibility to further interrogate the sources of heterogeneity as additional data are available.  
345 A distinct advantage of the modelling approach we used for algorithm development is the ability  
346 to revise and calibrate the model to specific settings as additional data become available.

347         We considered it important to evaluate existing treatment-decision algorithms and  
348 develop new algorithms using a composite standard rather than solely a microbiological  
349 standard, given the high percentage of children treated for tuberculosis without bacteriological  
350 confirmation, even in the best resourced settings, which reflects the paucibacillary nature of  
351 disease in most young children. However, this reference standard remains imperfect, and  
352 misclassification may occur.<sup>27</sup> The underlying composition of the unconfirmed tuberculosis  
353 group may represent a heterogeneous group in which some children have tuberculosis, and  
354 some have other causes for their observed symptoms and signs. Additionally, it is possible that  
355 inclusion of unconfirmed pulmonary tuberculosis biased the estimation of the prediction model  
356 parameters, especially those used to classify the unconfirmed group. Although this is a limitation  
357 of our study, the similar performance estimates of the score developed in the primary analysis  
358 using both the composite and confirmed tuberculosis reference standards suggest that this may  
359 not be a major issue.

360         Given that our algorithms are intended to guide decisions to treat children in primary  
361 healthcare centres, it is a limitation that IPD was derived from primarily tertiary and referral  
362 health centres. We are not aware of studies that provide this quality of diagnostic evaluations  
363 data from presumptive childhood tuberculosis in primary healthcare centres. However, in  
364 several studies, children presenting at primary healthcare settings were directly referred for

365 study evaluation, providing some degree of reassurance as to the generalisability of results. The  
366 pre-test probability of tuberculosis (i.e., the prevalence) is likely substantially lower among  
367 children attending primary healthcare centres and the clinical presentation may be different as  
368 compared to tertiary and referral centres from which the data were obtained. These are  
369 important given that many children with tuberculosis first present to primary healthcare  
370 centres.<sup>28</sup> We believe that the risk-stratification and delayed entry of lower risk children with  
371 presumptive tuberculosis (who should tolerate the delay) is a practical attempt to safely raise  
372 the pre-test probability when implementing the algorithm in primary health centres. Prospective  
373 external validation of the entire algorithms will be critical to determining their accuracy,  
374 acceptability and feasibility of use at different levels of the healthcare system.

375         There are inherent limitations to developing a prediction model developed on data from  
376 multiple cohorts for a disease with an imperfect diagnostic gold standard. Study inclusion criteria  
377 varied, which impacts the baseline tuberculosis prevalence and applicability of the score  
378 prediction estimates. Additionally, prediction variable definitions varied among the included  
379 studies—for example, history of weight loss was variably defined as caregiver reported history  
380 of weight loss or objective weight loss and/or deviation from previous growth trajectory. This  
381 heterogeneity is also true for the study-level reference classifications, especially for unconfirmed  
382 tuberculosis. Some studies used a previous version of the NIH reference classification, which  
383 included probable and possible tuberculosis categories that we reclassified as unconfirmed  
384 tuberculosis, despite limitations using this approach.<sup>29</sup> These may contribute to heterogeneities  
385 in estimating the association between the predictors and the outcome of tuberculosis. Finally,  
386 we note that using a prespecified prediction model, as we did, may lead to overfitting.<sup>30</sup> Despite  
387 a reasonable summary O:E ratio for our model, the heterogeneity in study-level O:E ratio  
388 demonstrated in our internal-external cross-validation suggests that overfitting may be an issue.  
389 As more data become available, future investigation into the causes driving heterogeneity may  
390 inform more nuanced use of this algorithm within specific contexts and populations.



391 Pragmatic treatment-decision algorithms can lead to better detection of tuberculosis in  
392 children, with improved access to early treatment and reduced tuberculosis morbidity and  
393 mortality. Although we developed these algorithms using a thorough modelling analysis of a  
394 large high-quality IPD dataset, the disappointing specificity of the scoring component suggests  
395 that improved diagnostic tools will be necessary to meet sensitivity and specificity targets. As  
396 these diagnostic tools are identified, their data may be incorporated into treatment-decision  
397 algorithms to improve the specificity of the algorithms while maintaining high sensitivity.  
398 Additionally, decision-analytic modelling of the relative “cost” of false positive versus false  
399 negative classification of tuberculosis and prevalence of tuberculosis may provide insight to  
400 select an appropriate sensitivity threshold in future algorithm development.

401 Treatment-decision algorithms are now conditionally recommended by the WHO in the  
402 evaluation of children with presumptive tuberculosis, which should lead to improved diagnostic  
403 capacity at and treatment initiation at primary healthcare centres where paediatric tuberculosis  
404 expertise may be lacking. This work represents a paradigm shift in pragmatic and evidence-  
405 based approaches using advanced analytic methods to develop algorithms that draw on the  
406 best globally available data. This approach can be further improved and interrogated as  
407 additional data and diagnostic tools become available.

408

409 **REFERENCES**

- 410 1. World Health Organization. Global tuberculosis report 2021. Geneva: World Health  
411 Organization; 2021.
- 412 2. Perin J, Mulick A, Yeung D, et al. Global, regional, and national causes of under-5  
413 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable  
414 Development Goals. *Lancet Child Adolesc Health* 2022; **6**(2): 106-15.
- 415 3. Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of  
416 tuberculosis mortality in children: a mathematical modelling study. *Lancet Glob Health* 2017;  
417 **5**(9): e898-e906.
- 418 4. Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the diagnosis of  
419 pulmonary tuberculosis in children: a systematic review and meta-analysis. *Lancet Resp Med*  
420 2015; **3**(6): 451-61.
- 421 5. Naidoo P, Theron G, Rangaka MX, et al. The South African tuberculosis care cascade:  
422 estimated losses and methodological challenges. *J Infect Dis* 2017; **216**(Suppl 7): S702-S13.
- 423 6. Wobudeya E, Jaganath D, Sekadde MP, Nsangi B, Haq H, Cattamanchi A. Outcomes of  
424 empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015. *BMC Public Health*  
425 2019; **19**(1): 446.
- 426 7. Zawedde-Muyanja S, Nakanwagi A, Dongo JP, et al. Decentralisation of child  
427 tuberculosis services increases case finding and uptake of preventive therapy in Uganda. *Int J*  
428 *Tuberc Lung Dis* 2018; **22**(11): 1314-21.
- 429 8. Van Brusselen D, Simons E, Luendo T, et al. Improving pediatric TB diagnosis in North  
430 Kivu (DR Congo), focusing on a clinical algorithm including targeted Xpert MTB/RIF on gastric  
431 aspirates. *Confl Health* 2020; **14**: 26.
- 432 9. Fourie PB, Becker PJ, Festenstein F, et al. Procedures for developing a simple scoring  
433 method based on unsophisticated criteria for screening children for tuberculosis. *Int J Tuberc*  
434 *Lung Dis* 1998; **2**(2): 116-23.
- 435 10. Gunasekera KS, Walters E, van der Zalm MM, et al. Development of a treatment-  
436 decision algorithm for human immunodeficiency virus–uninfected children evaluated for  
437 pulmonary tuberculosis. *Clin Infect Dis* 2021.
- 438 11. Marcy O, Borand L, Ung V, et al. A treatment-decision score for HIV-infected children  
439 with suspected tuberculosis. *Pediatrics* 2019; **144**(3): e20182065.
- 440 12. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5:  
441 management of tuberculosis in children and adolescents. Geneva: World Health Organization;  
442 2022.
- 443 13. World Health Organization. WHO operational handbook on tuberculosis. Module 5:  
444 management of tuberculosis in children and adolescents. Geneva: World Health Organization;  
445 2022.
- 446 14. Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical case definitions for classification  
447 of intrathoracic tuberculosis in children: an update. *Clin Infect Dis* 2015; **61**: s179-87.
- 448 15. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing  
449 the quality of nonrandomised studies in meta-analyses  
450 [https://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).

- 451 16. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained  
452 equations in R. *J Stat Softw* 2011; **45**(3): 1-67.
- 453 17. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH.  
454 Bivariate analysis of sensitivity and specificity produces informative summary measures in  
455 diagnostic reviews. *J Clin Epidemiol* 2005; **58**(10): 982-90.
- 456 18. Doebler P. mada: Meta-analysis of diagnostic accuracy. 2020.
- 457 19. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a  
458 multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD  
459 statement. *Br Med J* 2015; **350**: g7594.
- 460 20. Debray TP, Damen JA, Riley RD, et al. A framework for meta-analysis of prediction  
461 model studies with binary and time-to-event outcomes. *Stat Methods Med Res* 2019; **28**(9):  
462 2768-86.
- 463 21. Debray T, de Jong V. metamisc: meta-analysis of diagnosis and prognosis research  
464 studies. R package version 0.2.4/r584. <https://R-Forge.R-project.org/projects/metamisc/>. 2021.
- 465 22. Heymans MW, Eekhout I. Applied missing data analysis with SPSS and (R)Studio; 2019.
- 466 23. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3:  
467 diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health  
468 Organization; 2021.
- 469 24. Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in  
470 African and Indian children. *N Engl J Med* 2022; **386**(10): 911-22.
- 471 25. World Health Organization. High-priority target product profiles for new tuberculosis  
472 diagnostics: report of a consensus meeting. Geneva, Switzerland; 2014.
- 473 26. Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in  
474 children: review. *Trop Med Int Health* 2009; **14**(11): 1329-37.
- 475 27. Wong M, Coit JM, Mendoza M, et al. Incident tuberculosis diagnoses in children at high  
476 risk for disease. *Open Forum Infect Dis* 2021; **8**(3).
- 477 28. Zawedde-Muyanja S, Reuter A, Tovar MA, et al. Provision of decentralized TB care  
478 services: a detect-teat-prevent strategy for children and adolescents affected by TB. *Pathogens*  
479 2021; **10**(12): 1568.
- 480 29. Marcy O, Goyet S, Borand L, et al. Tuberculosis diagnosis in HIV-infected children:  
481 comparison of the 2012 and 2015 clinical case definitions for classification of intrathoracic  
482 tuberculosis disease. *J Pediatr Infect Dis* 2021.
- 483 30. Steyerberg E. Clinical prediction models: a practical approach to development,  
484 validation, and updating. New York, NY: Springer-Verlag New York; 2009.

485

## 486 **AUTHOR CONTRIBUTIONS**

487 Conceptualization: KSG, OM, JAS

488 Data curation: KSG, OM, EL-V, MFF, MB, SA, FA, AA, OA, RBA, SB, IB, KPC, LC, MC, ESC,

489 ALG-B, ACH, JH, SK, LL, AAM, KM, DN, MPN, PO, MP, CCS, SAS, JPS, RS, NTTTT, VU,

490 MMvdZ, EGW, HJZ

491 Formal analysis: KSG, OM, JM, JLW, TPAD, TC, JAS  
492 Funding acquisition: KSG, AB, SV, KV, TC, JAS  
493 Investigation: KSG, OM, JM, EL-V, MPS, MFF, MB, SA, FA, AA, OA, RBA, SB, IB, AB, KPC,  
494 LC, MC, ESC, ALG-B, ACH, JH, SK, AM, FM, AAM, KM, DN, MPN, PO, MP, CCS, SAS, JPS,  
495 RS, NTTTT, VU, MMvdZ, SV, KV, EGW, JLW, HJZ, BJM, SMG, TPAD, TC, JAS  
496 Methodology: KSG, OM, JM, AB, SV, KV, TPAD, TC, JAS  
497 Software: JM, TPAD  
498 Validation: KSG, JAS  
499 Visualization: KSG  
500 Writing - original draft: KSG, TC, JAS  
501 Writing - review & editing: all authors

## 502 **ROLE OF THE FUNDING SOURCE**

503 This work was supported by the WHO Global Tuberculosis Programme (GTB) as well as  
504 the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the  
505 United States National Institutes of Health (NIH). It was used to inform WHO consolidated  
506 guidelines on tuberculosis management of TB in children and adolescents and the  
507 accompanying operational handbook, both published by WHO in March 2022. This research  
508 was also supported in part by the President's Emergency Plan for AIDS Relief (PEPFAR)  
509 through the Centers for Disease Control and Prevention (CDC).

### 510 *Disclaimer*

511 Staff from the WHO GTB as well as staff from the CDC are co-authors of this paper,  
512 offered feedback on the methodology and investigation, reviewed the manuscript, and made the  
513 decision to submit. The authors alone are responsible for the views expressed in this article and  
514 they do not necessarily represent the views, decisions or policies of the NIH, the WHO, the  
515 CDC, and PEPFAR.

516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540

**ACKNOWLEDGEMENTS**

KSG was supported by the NIH the Eunice Kennedy Shriver National Institute of Child Health and Human Development [F30HD105440] as well as the Yale Medical Scientist Training Program [T32GM007205]. SA, SB and SK received funding support from USAID through Research for Decision Makers' Activity, and the paper was prepared through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Program for Research and Training in Tropical Diseases at the World Health Organization. LMC was supported by the NIH/NIAID (K23 AI143479). RS was supported by the NIH through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K23HD072802). MMVDZ is supported by a career development grant from the EDCTP2 program supported by the European Union (TMA2019SFP-2836 TB lung-FACT2), the Fogarty International Center of the National Institutes of Health (Award Number K43TW011028) and by funding from the South African Medical Research Council. EW was supported by a scholarship for doctoral studies from the Medical Research Council of South Africa under MRC Clinician Researcher Programme, the Faculty of Medicine and Health Sciences at Stellenbosch University (Early Career Grant and Temporary Research Assistantship grant), the Harry Crossley Foundation and the South African National Research Foundation (Thuthuka programme funding for doctoral students). HJZ and MPN received funding from the NIH (R01HD058971) and the Regional Prospective Observational Research in Tuberculosis Consortium, co-funded by MRC of South Africa and NIH. TC and JLW were supported by the NIH through the Institute of Allergy and Infectious Disease [R01AI147854 and R01AI137093, respectively]. JAS was supported by a Clinician Scientist Fellowship jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (MR/R007942/1).

541 We acknowledge the patients and their caregivers for their willingness to participate in  
542 each individual study. We hope that their contribution will benefit other families affected by  
543 tuberculosis. We additionally would like to thank the following individuals who contributed to  
544 execution of this work: Albert Okumu, Andrea T. Cruz, Carlos M. Perez-Velez, Chad Heilig,  
545 Colleen Wright, Elisha Okeyo, Ha Thi Minh Đang, Hendrik Simon Schaaf, James Orwa, Lazarus  
546 Odeny, Lesley Workman, Maria R. Jaswal, Mariaem Andres, Mark Fajans, Moe Zaw, Parisa  
547 Hariri, Patrice Ahenda, Prisca Rabuogi, Rose Abwunza, Rumana Nasrin, Sabrina Choudhury,  
548 Scott Lee, Shaikh Shumail, Shoaib Ahmed, Susan Musau, Syed Mohammad Mazidur Rahman,  
549 Walter Mchembere, Yi Kyaw, Leonardo Martinez, Vivian Cox, Bryan Vonasek, and Alexander  
550 Kay. Finally, we would like to acknowledge the members of the WHO Guideline Development  
551 Group who considered this evidence to inform the 2022 WHO consolidated guidelines on the  
552 management of tuberculosis in children and adolescents.

553

#### 554 **DATA AVAILABILITY**

555 Data is available upon written request to the authors.

556 **TABLES**

557 **Table 1. Study-level descriptions of data included in the individual participant dataset.** HIV – human immunodeficiency virus, SAM –  
 558 severely acutely malnourished, PTB – pulmonary tuberculosis, Refs – references, BD – Bangladesh, BR – Brazil, KE – Kenya, MM – Myanmar,  
 559 Multi – Multi-country study (includes Burkina Faso, Cameroon, Vietnam, and Cambodia), MZ – Mozambique, PK – Pakistan, UG – Uganda, VN –  
 560 Vietnam, ZA – South Africa. \*Note: Modified version of the Newcastle-Ottawa Scale for cohort studies.

Study	Size N	<2 years N (%)	<5 years N (%)	HIV N (%)	SAM N (%)	Confirmed PTB N (%)	Unconfirmed PTB N (%)	Unlikely PTB N (%)	NOS*
Aurilio/2020/BR	50	21 (42)	31 (62)	6 (12)	0 (0)	9 (18)	11 (22)	24 (48)	5/5
Giang/2015/VN	113	86 (76)	106 (94)	0 (0)	8 (7)	20 (18)	77 (68)	16 (14)	5/5
Hamid/2019/PK	445	41 (9)	175 (39)	0 (0)	26 (6)	0 (0)	29 (7)	416 (93)	5/5
Kabir/2020/BD	402	219 (54)	296 (74)	0 (0)	93 (23)	63 (16)	36 (9)	303 (75)	4/5
LopezVarela/2015/MZ	789	549 (70)	789 (100)	104 (13)	68 (9)	13 (2)	128 (16)	648 (82)	4/5
Marcy/2019/Multi	338	78 (23)	142 (42)	338 (100)	64 (19)	41 (12)	155 (46)	142 (42)	5/5
Myo/2018/MM	223	72 (32)	150 (67)	27 (12)	46 (21)	27 (12)	84 (38)	112 (50)	5/5
Orikiriza/2018/UG	338	124 (37)	222 (66)	101 (30)	41 (12)	12 (4)	145 (43)	167 (49)	5/5
Orikiriza/2022/UG	217	157 (72)	196 (90)	70 (32)	108 (50)	12 (6)	58 (27)	125 (58)	4/5
Song/2021/KE	300	146 (49)	300 (100)	73 (24)	8 (3)	31 (10)	65 (22)	170 (57)	4/5
Valencia/2017/MZ	142	59 (42)	95 (67)	70 (49)	27 (19)	5 (4)	28 (20)	109 (77)	5/5
Walters/2017/ZA	595	389 (65)	548 (92)	70 (12)	18 (3)	119 (20)	180 (30)	283 (48)	5/5
Zar/2019/ZA	766	362 (47)	603 (79)	137 (18)	32 (4)	189 (25)	274 (36)	303 (40)	5/5
<b>Total IPD</b>	<b>4 718</b>	<b>2 303 (49)</b>	<b>3 653 (77)</b>	<b>996 (21)</b>	<b>539 (11)</b>	<b>541 (11)</b>	<b>1 270 (27)</b>	<b>2 818 (60)</b>	

561

562 **Table 2. Characteristics of individual participant dataset.** All clinical, bacteriology, and imaging data  
563 collected from the initial evaluation. IPD – Individual participant data, IQR – interquartile range, BCG –  
564 bacille Calmette-Guerin, HIV – human immunodeficiency virus, Mtb – *Mycobacterium tuberculosis*, CXR –  
565 chest x-ray, TST – tuberculin skin test.

Variable	Value	Confirmed tuberculosis (N=541)	Unconfirmed tuberculosis (N=1 270)	Unlikely tuberculosis (N=2 818)
		n (%) OR median (IQR)	n (%) OR median (IQR)	n (%) OR median (IQR)
Age	Months	25.6 (12,58.7)	24.1 (12,53.6)	24.4 (13.4,54)
	Unknown	0 (0)	0 (0)	0 (0)
Sex	Male	285 (53)	715 (56)	1512 (54)
	Female	256 (47)	554 (44)	1306 (46)
	Unknown	0 (0)	1 (0)	0 (0)
Weight-for-age	z-score	-1.7 (-2.9,-0.6)	-1.7 (-2.9,-0.6)	-1.8 (-3,-0.7)
	Unknown	7 (1)	16 (1)	119 (4)
BCG vaccination	Evidence of BCG vaccination	462 (85)	1 084 (85)	2 105 (75)
	No evidence of BCG vaccination	45 (8)	89 (7)	152 (5)
	Unknown	34 (6)	97 (8)	561 (20)
HIV status	HIV-positive	111 (21)	396 (31)	464 (16)
	HIV-negative	425 (79)	841 (66)	2 254 (80)
	Unknown	5 (1)	33 (3)	100 (4)
Cough duration	No cough	75 (14)	205 (16)	823 (29)
	Cough 0-13 days	148 (27)	279 (22)	598 (21)
	Cough 14-20 days	90 (17)	140 (11)	321 (11)
	Cough 21-27 days	52 (10)	96 (8)	224 (8)
	Cough >27 days	125 (23)	260 (20)	512 (18)
	Unknown	51 (9)	290 (23)	340 (12)
Cough ≥ 2 weeks	Cough ≥2 weeks present	295 (55)	697 (55)	1 247 (44)
	Cough ≥2 weeks not present	238 (44)	562 (44)	1531 (54)
	Unknown	8 (1)	11 (1)	40 (1)
Fever duration	No fever	146 (27)	352 (28)	1 157 (41)
	Fever 0-13 days	136 (25)	281 (22)	712 (25)
	Fever 14-20 days	67 (12)	122 (10)	262 (9)
	Fever 21-27 days	20 (4)	40 (3)	88 (3)
	Fever >27 days	77 (14)	119 (9)	184 (7)
	Unknown	95 (18)	356 (28)	415 (15)
Fever ≥1 week	Fever ≥1 week present	209 (39)	388 (31)	779 (28)
	Fever ≥1 week not present	242 (45)	650 (51)	1 776 (63)
	Unknown	90 (17)	232 (18)	263 (9)
Lethargy	Lethargy	268 (50)	479 (38)	838 (30)
	No lethargy	226 (42)	565 (44)	1 204 (43)
	Unknown	47 (9)	226 (18)	776 (28)
Weight loss	Weight loss	358 (66)	763 (60)	1 631 (58)
	No weight loss	172 (32)	492 (39)	1 155 (41)
	Unknown	11 (2)	15 (1)	32 (1)
Documented tuberculosis exposure	Documented tuberculosis exposure in previous 12 months	257 (48)	491 (39)	497 (18)
	No documented tuberculosis exposure in previous 12 months	284 (52)	775 (61)	2315 (82)
	Unknown	0 (0)	4 (0)	6 (0)
Night sweats	Night sweats	206 (38)	422 (33)	568 (20)
	No night sweats	187 (35)	577 (45)	1 845 (65)
	Unknown	148 (27)	271 (21)	405 (14)
Haemoptysis	Haemoptysis	2 (0)	13 (1)	12 (0)
	No haemoptysis	88 (16)	410 (32)	851 (30)
	Unknown	451 (83)	847 (67)	1 955 (69)
Objective fever (≥38 degrees Celsius)	Objective fever	71 (13)	101 (8)	156 (6)
	No objective fever	228 (42)	738 (58)	1 476 (52)
	Unknown	242 (45)	431 (34)	1 186 (42)
Tachycardia	Tachycardia	80 (15)	150 (12)	175 (6)



	<i>No tachycardia</i>	179 (33)	611 (48)	1 187 (42)
	<i>Unknown</i>	282 (52)	509 (40)	1 456 (52)
<b>Tachypnoea</b>	<i>Tachypnoea</i>	128 (24)	264 (21)	320 (11)
	<i>No tachypnoea</i>	276 (51)	742 (58)	1 494 (53)
	<i>Unknown</i>	137 (25)	264 (21)	1 004 (36)
<b>Peripheral lymphadenopathy</b>	<i>Peripheral lymphadenopathy</i>	134 (25)	242 (19)	280 (10)
	<i>No peripheral lymphadenopathy</i>	295 (55)	759 (60)	1 444 (51)
	<i>Unknown</i>	112 (21)	269 (21)	1 094 (39)
<b>First Xpert MTB/RIF</b>	<i>Xpert positive for Mtb</i>	247 (46)	0 (0)	0 (0)
	<i>Xpert negative for Mtb</i>	273 (50)	1148 (90)	2 306 (82)
	<i>Unknown/not performed</i>	21 (4)	122 (10)	512 (18)
<b>Overall CXR read</b>	<i>CXR consistent with tuberculosis</i>	344 (64)	644 (51)	653 (23)
	<i>CXR not consistent with tuberculosis</i>	101 (19)	474 (37)	1 744 (62)
	<i>Unknown/not assessed</i>	96 (18)	152 (12)	421 (15)
<b>Opacities on CXR</b>	<i>Opacities present on CXR</i>	237 (44)	487 (38)	594 (21)
	<i>Opacities not present on CXR</i>	154 (28)	459 (36)	1 042 (37)
	<i>Unknown/not assessed</i>	150 (28)	324 (26)	1 182 (42)
<b>Cavities on CXR</b>	<i>Cavities present on CXR</i>	32 (6)	25 (2)	20 (1)
	<i>Cavities not present on CXR</i>	348 (64)	793 (62)	973 (35)
	<i>Unknown/not assessed</i>	161 (30)	452 (36)	1 825 (65)
<b>Miliary infiltrate on CXR</b>	<i>Miliary infiltrate present on CXR</i>	33 (6)	19 (1)	7 (0)
	<i>Miliary infiltrate not present on CXR</i>	358 (66)	927 (73)	1 614 (57)
	<i>Unknown/not assessed</i>	150 (28)	324 (26)	1 197 (42)
<b>Intrathoracic lymphadenopathy on CXR</b>	<i>Intrathoracic lymphadenopathy present on CXR</i>	154 (28)	248 (20)	104 (4)
	<i>Intrathoracic lymphadenopathy not present on CXR</i>	237 (44)	684 (54)	1 485 (53)
	<i>Unknown/not assessed</i>	150 (28)	338 (27)	1 229 (44)
<b>Pleural effusion on CXR</b>	<i>Pleural effusion present on CXR</i>	56 (10)	63 (5)	49 (2)
	<i>Pleural effusion not present on CXR</i>	335 (62)	883 (70)	1 570 (56)
	<i>Unknown/not assessed</i>	150 (28)	324 (26)	1 199 (43)
<b>Tuberculin skin test</b>	<i>TST positive</i>	298 (55)	464 (37)	262 (9)
	<i>TST negative</i>	174 (32)	674 (53)	1 972 (70)
	<i>Unknown/not performed</i>	69 (13)	132 (10)	584 (21)

567 **Table 3. Estimates from logistic regression prediction model to classify pulmonary tuberculosis**  
 568 **using variables from initial evaluation.** Parameter estimate with 95% confidence intervals, odds ratio  
 569 estimate with 95% confidence interval, and p-values for each parameter included in the logistic regression  
 570 prediction model. The estimate provided for each predictor is computed against a reference that reflects  
 571 the absence of that feature. The model parameter estimates account for potential clustering at the study-  
 572 level as well as uncertainty introduced by missing data. \*P-value calculated using Rubin's rules for  
 573 multiple imputed data. OR – odds ratio, CI – confidence interval, CXR – chest x-ray.



Predictors	Coefficient	Coefficient 95% CI	OR	OR 95% CI	P-value*
Intercept	-1.92	-2.58, -1.25	--	--	--
<b>Cough duration ≥2 weeks (Absence is no cough or cough &lt;2 weeks)</b>	0.17	-0.09, 0.43	1.19	0.91, 1.54	0.86
<b>Fever duration ≥2 weeks (Absence is no fever or fever &lt;2 weeks)</b>	0.45	0.16, 0.74	1.57	1.18, 2.09	0.25
<b>Lethargy</b>	0.25	0.02, 0.48	1.28	1.02, 1.62	0.66
<b>Weight loss</b>	0.22	-0.03, 0.48	1.25	0.97, 1.62	0.75
<b>History of documented tuberculosis exposure</b>	1.43	0.87, 2.00	4.20	2.39, 7.38	<0.001
<b>Haemoptysis</b>	0.34	-0.37, 1.05	1.40	0.69, 2.86	0.78
<b>Night sweats</b>	0.2	0.02, 0.38	1.22	1.02, 1.47	0.71
<b>Peripheral lymphadenopathy</b>	0.35	0.13, 0.57	1.42	1.14, 1.77	0.35
<b>Temperature ≥38 Celsius</b>	0.00	-0.25, 0.26	1.00	0.78, 1.30	>0.999
<b>Tachycardia</b>	0.15	-0.13, 0.42	1.16	0.88, 1.53	0.90
<b>Tachypnoea</b>	-0.05	-0.27, 0.16	0.95	0.77, 1.18	0.98
<b>Cavities on CXR</b>	0.47	-0.11, 1.05	1.60	0.90, 2.85	0.53
<b>Intrathoracic lymphadenopathy on CXR</b>	1.46	1.00, 1.92	4.32	2.73, 6.85	<0.001
<b>Opacities on CXR</b>	0.43	0.02, 0.84	1.54	1.02, 2.32	0.45
<b>Miliary infiltrate on CXR</b>	1.27	0.57, 1.97	3.56	1.76, 7.19	<0.001
<b>Pleural effusion on CXR</b>	0.64	0.2, 1.09	1.90	1.22, 2.96	0.13

574


575 **FIGURES**

576 **Figure 1. Performance of existing treatment-decision algorithms at classifying tuberculosis.**

577 Retrospective estimates of the pooled **(A)** sensitivity and **(B)** specificity of eight algorithms to guide  
578 decisions to treat children with presumptive pulmonary tuberculosis, had they been used to evaluate the  
579 children for whom we have IPD records. The reference classification of pulmonary tuberculosis included  
580 bacteriologically-confirmed pulmonary tuberculosis as well as unconfirmed pulmonary tuberculosis.  
581 Modifications were made to the algorithms to maximise the use of the available IPD. IPD – individual  
582 participant data, HIV – human immunodeficiency virus, BD – Bangladesh, BR – Brazil, KE – Kenya, MM –  
583 Myanmar, Multi – (PAANTHER) Multi-country study (includes Burkina Faso, Cameroon, Vietnam, and  
584 Cambodia), MZ – Mozambique, PK – Pakistan, UG – Uganda, VN – Vietnam, ZA – South Africa, MoH –  
585 (Brazil) Ministry of Health, NTLP – (Uganda) National TB and Leprosy Program. \*Performance estimates  
586 of the Marcy et al. Algorithm were derived from only HIV-positive children in the IPD that excludes data  
587 from the Marcy/2016/Multi cohort (from which the algorithm was developed), \*\*Performance estimates of  
588 the Gunasekera et al. Algorithm were derived from only HIV-negative children in the IPD that excludes  
589 data from the Walter/2017/ZA population (from which the algorithm was developed).



591 **Figure 2. Forest plot depicting performance of scaled scores from prediction model to classify**  
 592 **tuberculosis with 85% sensitivity.** Study-level and pooled estimates of the **(A)** sensitivity and **(B)**  
 593 specificity of classifying tuberculosis (composite reference standard: bacteriologically-confirmed  
 594 pulmonary tuberculosis and unconfirmed pulmonary tuberculosis) of the scores derived from the  
 595 prediction model developed from the IPD to classify TB with 85% sensitivity. IPD – individual participant  
 596 data, BD – Bangladesh, BR – Brazil, KE – Kenya, MM – Myanmar, Multi – Multi-country study (includes  
 597 Burkina Faso, Cameroon, Vietnam, and Cambodia), MZ – Mozambique, PK – Pakistan, UG – Uganda,  
 598 VN – Vietnam, ZA – South Africa.




599  
 600  
 601

602 **Figure 3. Treatment-decision algorithm including chest x-ray features derived from the prediction**  
603 **model.** Tuberculosis treatment-decision algorithm for use among children <10 years with symptoms  
604 suggestive of pulmonary tuberculosis, reproduced from the operational handbook accompanying the  
605 WHO consolidated guidelines on the management of tuberculosis in children and adolescents.<sup>12,13</sup>  
606 Selection steps prior to entering scoring system reflect recommendations from the WHO expert panel to  
607 enrich the probability of tuberculosis among the population of children proceeding through the algorithm  
608 to the model such that the probability would more closely reflect the preselected population producing the  
609 data from which the prediction model was built while balancing the consequences of untreated  
610 tuberculosis among high-risk children. Scores associated with features from clinical history and physical  
611 exam and chest X-ray translate to risk of tuberculosis and are scaled from the prediction model  
612 developed from the IPD. Guidance on the practical use of this algorithm is outlined in the WHO  
613 operational handbook. WHO – World Health Organization, TB – tuberculosis, IPD – individual participant  
614 data, HIV – human immunodeficiency virus, mWRD – molecular WHO-recommended rapid diagnostic  
615 test, CLHIV – children living with HIV, LF-LAM – lateral flow urine lipoarabinomannan assay, CXR – chest  
616 X-ray.

**Child <10 years with symptoms suggestive of pulmonary TB**

**Algorithm A**



618 **AUTHOR AFFILIATIONS**

619 Name: Kenneth S. Gunasekera

620 Degree: PhD

621 Affiliation(s):

622 1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New  
623 Haven, USA

624

625 Name: Olivier Marcy

626 Degree: PhD

627 Affiliation(s):

628 1. University of Bordeaux, Inserm UMR1219, Institut de Recherche pour le Développement  
629 (IRD) EMR 271, Bordeaux France

630

631 Name: Johanna Muñoz

632 Degree: M.Sc.

633 Affiliation(s):

634 1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,  
635 Utrecht University, Utrecht, The Netherlands

636

637 Name: Elisa Lopez-Varela

638 Degree: MD, PhD

639 Affiliation(s):

640 1. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona,  
641 Barcelona, Spain

642

643 Name: Moorine Penninah Sekadde

644 Degree: MD

645 Affiliation(s):

646 1. National Tuberculosis and Leprosy Program, Kampala, Uganda

647

648 Name: Molly F. Franke

649 Degree: ScD

650 Affiliation(s):

651 1. Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA

652

653 Name: Maryline Bonnet

654 Degree: MD, PhD

655 Affiliation(s):

656 1. University of Montpellier, Inserm, Institut de Recherche pour le Développement, TransVIHMI,  
657 Montpellier, France

658 2. Epicentre, Mbarara, Uganda

659

660 Name: Shakil Ahmed

661 Degree: FCPS

662 Affiliation(s):

663 1. Department of Paediatrics, Dhaka Medical College Hospital, Dhaka, Bangladesh

664

665 Name: Farhana Amanullah

666 Degree: FAAP

667 Affiliation(s):

668 1. Indus Hospital & Health Network, Karachi, Pakistan



669 2. The Aga Khan University Hospital, Karachi, Pakistan  
670  
671 Name: Aliya Anwar  
672 Degree: FCPS  
673 Affiliation(s):  
674 1. Indus Hospital & Health Network, Karachi, Pakistan  
675  
676 Name: Orvalho Augusto  
677 Degree: MD  
678 Affiliation(s):  
679 1. Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique  
680  
681 Name: Rafaela Baroni Aurilio  
682 Degree: MD, PhD  
683 Affiliation(s):  
684 1. Instituto de Puericultura e Pediatria Martagao Gesteira. Universidade Federal do Rio de  
685 Janeiro, Rio de Janeiro, Brazil  
686  
687 Name: Sayera Banu  
688 Degree: PhD  
689 Affiliation(s):  
690 1. Programme on Emerging Infections, Infectious Disease Division, icddr,b, Dhaka, Bangladesh  
691  
692 Name: Iraj Batool  
693 Degree: --  
694 Affiliation(s):  
695 1. Indus Hospital & Health Network, Karachi, Pakistan  
696  
697 Name: Annemieke Brands  
698 Degree: MPH  
699 Affiliation(s):  
700 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland  
701  
702 Name: Kevin P. Cain  
703 Degree: MD  
704 Affiliation(s):  
705 1. US Centers for Disease Control and Prevention, Atlanta, USA  
706  
707 Name: Lucía Carratalá-Castro  
708 Degree: MD  
709 Affiliation(s):  
710 1. Manhiça Health Research Centre, Maputo, Mozambique  
711 2. Barcelona Institute for Global Health, Barcelona, Spain  
712  
713 Name: Maxine Caws  
714 Degree: PhD  
715 Affiliation(s):  
716 1. Liverpool School of Tropical Medicine, Liverpool, UK  
717  
718 Name: Eleanor S. Click

719 Degree: MD  
720 Affiliation(s):  
721 1. US Centers for Disease Control and Prevention, Atlanta, USA  
722  
723 Name: Lisa M. Cranmer  
724 Degree: MD  
725 Affiliation(s):  
726 1. Emory School of Medicine, Atlanta, USA  
727 2. Emory Rollins School of Public Health, Atlanta, USA  
728 3. Children's Healthcare of Atlanta, Atlanta, USA  
729  
730 Name: Alberto L. García-Basteiro  
731 Degree: PhD  
732 Affiliation(s):  
733 1. Centro de Investigação em Saúde de Manhiça, CISM,e; Maputo, Mozambique  
734 2. ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain;  
735 3. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC),  
736 Barcelona, Spain  
737  
738 Name: Anneke C. Hesseling  
739 Degree: MD, PhD  
740 Affiliation(s):  
741 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine  
742 and Health Sciences, Stellenbosch University, Tygerberg, South Africa  
743  
744 Name: Julie Huynh  
745 Degree: MBBS  
746 Affiliation(s):  
747 1. Oxford University Clinical Research Unit, Centre for Tropical Diseases, Ho Chi Minh City,  
748 Vietnam  
749 2. Nuffield Department of Medicine, Oxford University, UK  
750  
751 Name: Senjuti Kabir  
752 Degree: MPH  
753 Affiliation(s):  
754 1. Programme on Emerging Infections, Infectious Disease Division, icddr,b, Dhaka, Bangladesh  
755  
756 Name: Leonid Lecca  
757 Degree: MD  
758 Affiliation(s):  
759 1. Socios En Salud Surcursal Perú, Lima, Perú  
760 2. Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA  
761  
762 Name: Anna Mandalakas  
763 Degree: PhD  
764 Affiliation(s):  
765 1. Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, USA  
766 2. Clinical Infectious Disease Group, German Center for Infectious Research (DZIF), Clinical TB  
767 Unit, Research Center Borstel, Borstel, Germany  
768  
769 Name: Farai Mavhunga

770 Degree: MPH  
771 Affiliation(s):  
772 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland  
773  
774 Name: Aye Aye Myint  
775 Degree: Dr.Med.Sc (Paediatrics)  
776 Affiliation(s):  
777 1. Department of Paediatrics, University of Medicine, Mandalay, Myanmar  
778  
779 Name: Kyaw Myo  
780 Degree: Dr.Med.Sc (Paediatrics)  
781 Affiliation(s):  
782 1. Department of Paediatrics, University of Medicine, Magway, Myanmar  
783  
784 Name: Dorah Nampijja  
785 Degree: MMed (Pediatrics)  
786 Affiliation(s):  
787 1. Mbarara University of Science and Technology, Mbarara, Uganda  
788  
789 Name: Mark P. Nicol  
790 Degree: PhD  
791 Affiliation(s):  
792 1. Division of Infection and Immunity, Department of Biomedical Sciences, University of Western  
793 Australia, Perth, Australia  
794  
795 Name: Patrick Orikiriza  
796 Degree: PhD  
797 Affiliation(s):  
798 1. Epicentre, Mbarara, Uganda  
799 2. Department of Microbiology, Division of Basic Medical Sciences, School of Medicine,  
800 University of Global Health Equity, Kigali, Rwanda  
801  
802 Name: Megan Palmer  
803 Degree: MMed  
804 Affiliation(s):  
805 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine  
806 and Health Sciences, Stellenbosch University, Tygerberg, South Africa  
807  
808 Name: Clemax Couto Sant'Anna  
809 Degree: PhD, MD  
810 Affiliation(s):  
811 1. Faculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil  
812  
813 Name: Sara Ahmed Siddiqui  
814 Degree: MBA  
815 Affiliation(s):  
816 1. Indus Hospital & Health Network, Karachi, Pakistan  
817  
818 Name: Jonathan P. Smith  
819 Degree: PhD  
820 Affiliation(s):

821 1. Department of Health Policy and Management, Yale School of Public Health, New Haven,  
822 USA  
823 2. US Centers for Disease Control and Prevention, Atlanta, USA  
824  
825 Name: Rinn Song  
826 Degree: MD  
827 Affiliation(s):  
828 1. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK  
829 2. Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts;  
830 3. Department of Pediatrics, Harvard Medical School, Boston, USA  
831  
832 Name: Nguyen Thuy Thuong Thuong  
833 Degree: PhD  
834 Affiliation(s):  
835 1. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam  
836 2. Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University  
837 of Oxford, Oxford, UK  
838  
839 Name: Vibol Ung  
840 Degree: MD  
841 Affiliation(s):  
842 1. University of Health Sciences, Phnom Penh, Cambodia  
843 2. National Pediatric Hospital, Phnom Penh, Cambodia  
844  
845 Name: Marieke van der Zalm  
846 Degree: PhD  
847 Affiliation(s):  
848 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine  
849 and Health Sciences, Stellenbosch University, Tygerberg, South Africa  
850  
851 Name: Sabine Verkuijl  
852 Degree: MD, MMed  
853 Affiliation(s):  
854 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland  
855  
856 Name: Kerri Viney  
857 Degree: PhD  
858 Affiliation(s):  
859 1. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland  
860 2. School of Public Health, University of Sydney, Sydney, Australia  
861  
862 Name: Elisabetta G. Walters  
863 Degree: PhD  
864 Affiliation(s):  
865 1. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine  
866 and Health Sciences, Stellenbosch University, Tygerberg, South Africa  
867 2. Directorate of Integrated Laboratory Medicine, Institute of Human Genetics, Newcastle upon  
868 Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom  
869  
870 Name: Joshua L. Warren  
871 Degree: PhD

872 Affiliation(s):  
873 1. Department of Biostatistics, Yale School of Public Health, New Haven, USA  
874  
875 Name: Heather J. Zar  
876 Degree: PhD  
877 Affiliation(s):  
878 1. Department of Paediatrics & Child Health, Red Cross Children's Hospital, Cape Town, South  
879 Africa  
880 2. SA-MRC Unit on Child & Adolescent Health, University of Cape Town, South Africa  
881  
882 Name: Ben J. Marais  
883 Degree: PhD  
884 Affiliation(s):  
885 1. The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health,  
886 University of Sydney, Sydney, Australia  
887  
888 Name: Stephen M. Graham  
889 Degree: PhD  
890 Affiliation(s):  
891 1. University of Melbourne Department of Paediatrics and Murdoch Children's Research  
892 Institute, Royal Children's Hospital, Melbourne, Australia  
893 2. Burnet Institute, Melbourne, Australia  
894  
895 Name: Thomas P. A. Debray  
896 Degree: PhD  
897 Affiliation(s):  
898 1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,  
899 Utrecht University, Utrecht, The Netherlands  
900  
901 Name: Ted Cohen  
902 Degree: DPH  
903 Affiliation(s):  
904 1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New  
905 Haven, USA  
906  
907 Name: James A. Seddon  
908 Degree: PhD  
909 Affiliation(s):  
910 1. Desmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of  
911 Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa  
912 2. Department of Infectious Diseases, Imperial College London, London, UK